Investors Menu
Tilray® Signs Letter of Intent for Hemp-Derived CBD from the U.S. and Canada
Company to utilize CBD isolate for distribution of wellness and medical products across North America NANAIMO, British Columbia --(BUSINESS WIRE)--Dec. 17, 2018-- Tilray, Inc. (NASDAQ:TLRY), a global leader in cannabis research and production, today announced the terms of a binding letter of intent
December 17, 2018
Tilray® Announces International Advisory Board
Ten internationally-renowned business and government leaders to advise company on global expansion NANAIMO, British Columbia --(BUSINESS WIRE)--Dec. 13, 2018-- Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced the formation of its International
December 13, 2018
Tilray® Announces New Subsidiary Tilray Latin America
Recently acquired subsidiary Alef Biotechnology officially renamed Tilray Latin America NANAIMO, British Columbia --(BUSINESS WIRE)--Dec. 3, 2018-- Tilray, Inc. (NASDAQ: TLRY) (“Tilray”), a global leader in cannabis research and production, today announced that after completing an acquisition of
December 3, 2018
Tilray, Inc. Reports Third Quarter 2018 Earnings
Revenue rises 85.8% to $10.0 (C$12.9) million in the third quarter and 78.9% to $27.6 (C$35.5) million year-to-date Tilray medical cannabis products available to patients in 12 countries on five continents Signed agreements to supply adult-use cannabis to consumers in eight Canadian provinces and
November 13, 2018
Tilray to Report Third Quarter 2018 Financial Results on November 13, 2018
NANAIMO, British Columbia --(BUSINESS WIRE)--Oct. 30, 2018-- Tilray Inc. (Nasdaq: TLRY), a global leader in cannabis production and distribution, announced today it will report results for the third quarter ended September 30, 2018 on Tuesday, November 13, 2018 after market close.
October 30, 2018